Skip to main content
    K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.03
    -0.27 (-2.62%)

    Market Cap: $202.13M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Keros Therapeutics Inc (KROS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Keros Therapeutics reported revenue of $244.06M for the fiscal year ended Dec 31, 2025, up 6775.0% from the year before. That year, net income was $87.01M with a net margin of 35.7%, operating cash flow was $107.50M and free cash flow was $105.95M. The quarter ended Sep 30, 2026 had revenue of $40.01M and net income of $14.15M.

    Revenue and Margins

    The operating margin was 27.7% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $10.00M, a compound annual rate of 57.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$244.06M+6775.0%100.0%27.7%35.7%
    Dec 2024$3.55M+2251.0%100.0%-5939.0%-5277.5%
    Dec 2023$151.00KN/A100.0%-112543.7%-101319.2%
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$20.10MN/A100.0%-280.5%-292.3%
    Dec 2020$0-100.0%N/AN/AN/A
    Dec 2019$10.00M0.0%100.0%-105.6%-123.4%
    Dec 2018$10.00MN/A-1.1%-16.9%-13.4%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$244.06M$3.55M$151.00K$0$20.10M$0$10.00M$10.00M
    Cost of revenue$0$0$0$0$0$0$0$10.11M
    Gross profit$244.06M$3.55M$151.00K$0$20.10M$0$10.00M-$111.00K
    Research and development$129.64M$173.63M$135.26M$87.27M$55.14M$33.86M$17.38M$10.11M
    Operating income$67.57M-$210.83M-$169.94M-$114.79M-$56.37M-$46.66M-$10.56M-$1.69M
    Net income$87.01M-$187.35M-$152.99M-$104.68M-$58.74M-$45.36M-$12.34M-$1.33M
    EBITDA$68.54M-$207.50M-$165.38M-$114.73M-$55.86MN/AN/A-$774.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$40.01M$0$367.00K$385.00K$14.26M$18.17M$211.25M$3.04M$388.00K$37.00K$83.00K$143.00K
    Gross profit$40.01M$0$367.00K$385.00K$14.26M$18.17M$211.25M$3.04M$388.00K$37.00K$83.00K$143.00K
    Operating income$12.82M-$30.94M-$25.88M-$29.27M-$15.38M-$39.82M$152.04M-$53.25M-$58.66M-$50.44M-$48.48M-$46.45M
    Net income$14.15M-$28.71M-$23.71M-$23.46M-$7.28M-$30.70M$148.45M-$46.03M-$52.96M-$45.26M-$43.11M-$40.24M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.41M by $285.01M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$338.02M$615.89M$370.02M$306.78M$255.25M$269.44M$10.96M$27.41M
    Current assets$315.43M$588.89M$347.29M$285.77M$251.44M$267.73M$8.93M$25.53M
    Cash and equivalents$287.42M$559.93M$331.15M$279.05M$230.04M$265.88M$7.02M$23.26M
    Total liabilities$34.89M$44.33M$37.81M$29.36M$12.08M$7.72M$10.46M$14.65M
    Short-term debt$2.41M$1.98M$1.00M$455.00K$862.00K$423.00K$376.00K$166.00K
    Long-term debtN/AN/AN/AN/AN/AN/A$4.96M$2.39M
    Shareholder equity$303.13M$571.55M$332.21M$277.42M$243.17M$261.72M-$19.45M$12.76M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$307.37M$287.60M$312.29M$338.02M$742.78M$757.16M$784.56M$615.89M$579.27M$455.02M$485.82M$370.02M
    Total liabilities$28.27M$25.28M$26.66M$34.89M$39.20M$50.43M$55.69M$44.33M$46.44M$34.11M$31.87M$37.81M
    Cash and equivalents$259.46M$257.61M$281.50M$287.42M$693.47M$690.22M$720.54M$559.93M$530.68M$405.86M$442.44M$331.15M
    Shareholder equity$279.10M$262.32M$285.63M$303.13M$703.58M$706.73M$728.87M$571.55M$532.84M$420.92M$453.95M$332.21M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 98.6% of operating cash flow. Share repurchases came to 353.9% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow$107.50M-$160.87M-$124.51M-$70.06M-$62.15M-$36.89M-$16.00M$7.04M
    Capital expenditures$1.56M$1.93M$2.46M$1.24M$1.02M$294.00K$271.00K$217.00K
    Free cash flow$105.95M-$162.80M-$126.97M-$71.30M-$63.17M-$37.19M-$16.27M$6.83M
    Share repurchases$375.00M$171.00K$94.00K$87.00KN/A$227.00K$0N/A
    Investing cash flow-$1.55M-$1.93M-$2.46M-$1.24M-$1.02M-$294.00K-$271.00K-$217.00K
    Financing cash flow-$378.47M$391.82M$178.96M$120.31M$28.55M$296.04M$14.00K$11.46M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$3.39M-$20.42M-$3.53M-$27.29M$3.25M-$29.62M$161.17M-$46.01M-$30.50M-$39.80M-$44.56M-$25.46M
    Capital expenditures$59.00K$155.00K$73.00K$134.00K$132.00K$720.00K$565.00K$289.00K$386.00K$310.00K$946.00K$541.00K
    Free cash flow$3.33M-$20.58M-$3.60M-$27.43M$3.12M-$30.34M$160.61M-$46.30M-$30.89M-$40.11M-$45.51M-$26.00M
    Last 12 quarters

    Frequently Asked Questions About KROS

    What is Keros Therapeutics' annual revenue?

    Keros Therapeutics reported revenue of $244.06M for the fiscal year ended Dec 31, 2025.

    How fast is Keros Therapeutics' revenue growing?

    Revenue was up 6775.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Keros Therapeutics profitable?

    Yes. Keros Therapeutics reported net income of $87.01M for the fiscal year ended Dec 31, 2025, with a net margin of 35.7%.

    How much free cash flow does KROS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $107.50M minus capital expenditures of $1.56M produced free cash flow of $105.95M.

    How much debt does Keros Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.41M and cash and equivalents of $287.42M.